Khandan Baradaran

Dr. Baradaran was Head of Quality at Dimension Therapeutics, which was acquired by Ultragenyx in 2017. Dr. Baradaran has extensive expertise in the areas of viral safety, gene therapy vector development, vaccine development, and assay technologies, and has held positions of increasing responsibility in regulatory affairs, quality control, and quality at Shire, Biogen, Dyax Corp., and Novartis Vaccines and Diagnostics. Khandan received her BA degree in molecular biology from Wellesley College and her Ph.D. in virology from Harvard University.